



Fertilized  
egg



2-cell  
stage




4-cell  
stage



8-cell  
stage



16-cell  
stage



Blastocyst



Foetus  
4-weeks



Foetus  
10-weeks





Foetus  
16-weeks



Foetus  
20-weeks


# Prokaryotic vs Eukaryotic Cell








DNA replication is the basis for the perpetuation of life through time




**Figure 1-14**  
*Introduction to Genetic Analysis, Tenth Edition*  
© 2012 W. H. Freeman and Company



**Figure 1-15**  
*Introduction to Genetic Analysis, Tenth Edition*  
© 2012 W. H. Freeman and Company

# Key stages of meiosis and mitosis

## Mitosis



## Meiosis





Figure 2-8


*Introduction to Genetic Analysis*, Tenth Edition

© 2012 W. H. Freeman and Company

## Disease prevalence and genetic model



From: Gilissen *et al. Genome Biology* 2011, **12:228**



?



gametes

	A	a
A	AA	Aa
a	Aa	aa

Autosomal recessive

P (healthy) = 3/4

P (affected) = 1/4

Two possible phenotypes

Three possible genotypes





# Autosomal recessive inheritance


Two copies of the mutant allele are necessary to produce an increase in risk, or equivalently, one copy of the normal allele is sufficient to provide protection.


Cystic Fibrosis (Chromosome 17)


1/ 2.000



$\frac{1}{4}$  healthy    $\frac{1}{2}$  carriers    $\frac{1}{4}$  affected









**Table 17.1** Human genetic relationships

Biological relationship	Genetic relationships	Coefficient of relationship	Coefficient of inbreeding
Incest <sup>a</sup>	First degree	0.5	0.25
Uncle-niece	Second degree	0.25	0.125
Double first cousin			
First cousin	Third degree	0.125	0.0625
First cousin once removed	Fourth degree	0.0625	0.0313
Double second cousin			
Second cousin	Fifth degree	0.0313	0.0156
Second cousin once removed	Sixth degree	0.0156	0.0078
Double third cousin			
Third cousin	Seventh degree	0.0078	0.0039

<sup>a</sup>Incest is defined as a sexual relationship between father–daughter, mother–son or brother–sister




**Fig. 17.1** Consanguineous pedigrees




B

Hypothesis	Carrier	Non-carrier
Prior Probability	$1/2$	$1/2$
Conditional Probability (of three normal sons)	$1/8$	$\sim 1$
Joint Probability	$1/16$	$1/2$
Posterior Probability	$(1/16) / (1/16 + 1/2) = 1/9$	$(1/2) / (1/16 + 1/2) = 8/9$













Aa Bb x Aa Bb



gametes

The Mendel's law of independent transmission is explained by the independent segregation of non homologous chromosomes during meiosis

Meiosis in a diploid cell  
with genotype (A/a; B/b)


Genotype AaBb


Gametes: AB  $\frac{1}{4}$

Ab  $\frac{1}{4}$

aB  $\frac{1}{4}$


ab  $\frac{1}{4}$





Aa Bb x Aa Bb

gametes




Do the observed proportions fit to the expected ones?


Do the observed proportions fit to the expected ones?

$$\chi^2 = \sum \frac{(\text{Observed value} - \text{Expected value})^2}{\text{Expected value}}$$

First pedigree




Second pedigree







I.




II.




III.




I.




II.



III.





<https://flxlexblog.wordpress.com/2016/07/08/developments-in-high-throughput-sequencing-july-2016-edition/>

# FASTQ files

Line1: Sequence identifier


Line2: Raw sequence

Line3: meaningless

Line4: quality values for the sequence


[illegible]

## Visualization





#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	BGMUB-1	BGMUB-2	BGMUB-3	BGMUB-C1	BGMUB-C2
13	20187061	rs9509085	C	T	100	PASS	AA=C     ;AC:GT	GT	1 1	1 1	1 0	1 1	1 1
13	20187624	rs7988691	A	G	100	PASS	AA=G     ;AC:GT	GT	1 1	1 1	1 1	1 1	1 1
13	20187749	rs7623	C	T	100	PASS	AA=T     ;AC:GT	GT	1 1	1 0	1 1	1 1	1 1
13	20187970	rs5030700	G	A	100	PASS	AA=G     ;AC:GT	GT	1 0	0 0	0 0	0 0	0 0
13	20188733	rs55704559	T	C	100	PASS	AA=T     ;AC:GT	GT	1 0	0 0	0 0	0 0	0 0
13	20188817	rs3751385	A	G	100	PASS	AA=G     ;AC:GT	GT	1 0	1 1	1 0	1 1	1 1
13	20188940	rs530484784	T	C	100	PASS	AA=T     ;AC:GT	GT	0 0	1 0	0 0	0 0	0 0
13	20189214	rs111033188	G	T	100	PASS	AA=G     ;AC:GT	GT	1 0	0 0	0 0	0 0	0 0
13	20189241	rs2274083	T	C	100	PASS	AA=T     ;AC:GT	GT	0 0	0 0	0 0	1 0	0 0
13	20189324	rs139362103	C	T	100	PASS	AA=C     ;AC:GT	GT	0 0	0 0	0 0	0 0	1 0
13	20189510	.	C	T	100	PASS	AA=T     ;AC:GT	GT	0 0	1 0	0 0	0 0	0 0
13	20189548	.	CC	C	100	PASS	AA=T     ;AC:GT	GT	0 0	1 0	0 0	0 0	0 0
13	20189596	rs72561725	G	A	100	PASS	AA=G     ;AC:GT	GT	0 0	0 0	1 0	0 0	0 0
13	20189783	rs73156818	A	T	100	PASS	AA=A     ;AC:GT	GT	0 0	0 0	0 0	1 0	0 0
13	20189935	rs7318163	G	T	100	PASS	AA=T     ;AC:GT	GT	1 1	1 1	1 0	1 1	1 1
13	20223243	.	G	C	100	PASS	AA=G     ;AC:GT	GT	1 1	0 0	0 0	0 0	0 0
13	20223280	rs554688212	G	T	100	PASS	AA=G     ;AC:GT	GT	0 0	0 0	1 0	0 0	0 0
13	20223451	rs377181573	G	A	100	PASS	AA=G     ;AC:GT	GT	0 0	0 0	1 0	0 0	0 0
13	20223475	rs200415730	A	G	100	PASS	AA=A     ;AC:GT	GT	0 0	1 0	0 0	0 0	0 0
13	20229254	rs145808643	T	C	100	PASS	AA=T     ;AC:GT	GT	0 0	1 0	0 0	0 0	1 0
13	20229305	rs71424089	T	C	100	PASS	AA=C     ;AC:GT	GT	0 0	0 0	1 0	0 0	0 0
13	20232512	rs148043721	C	CG	100	PASS	AA=? GGGG	GT	1 1	1 1	1 1	1 1	1 1
13	20232627	rs9506446	G	A	100	PASS	AA=G     ;AC:GT	GT	0 0	1 1	1 0	1 0	1 1



**1. HOW MANY VARIANTS DOES THE GENOME HAVE?**



**2. WHICH TYPE?**

**3. WHAT EFFECT DO THEY HAVE?**

**4. WHAT IS THE BIOLOGICAL SIGNIFICANCE?**

**Table 2** Frequency of different types of mutations that result in PKU


Type of PKU mutation	Percentage of all PKU mutations
Missense	67%
Deletion	14%
Splice	12%
Nonsense	6%
Insertion	1%



**Figure 1** Copies of the same mutation may be (a) identical by descent or (b) due to recurrent mutation.

### 3. WHAT EFFECT DO THEY HAVE?

## Functional annotation





### 3. EFFECT OF GENETIC VARIANTS

## Functional annotation

▪ synonymous



▪ splice donor

▪ missense

▪ frameshift

▪ intron

▪ stop gained



### 3. EFFECT OF GENETIC VARIANTS

## Functional annotation

Computational approaches to predict the impact of SNVs



**S**orting **I**ntolerant **F**rom **T**olerant substitutions (**SIFT**)

➤ Functionally important positions (e.g. active sites) tend to be conserved across species.

◆ Changes at conserved sites tend to be detrimental.

➤ Some positions show a high level of diversity across species.


♣ Changes at these positions tend to be neutral.



### 3. EFFECT OF GENETIC VARIANTS

## Functional annotation

Genetic variant	Position	Change	Consequence	Gene	Freq
<b>A</b>	3:1403401-1403401	A/C	missense	CNTN6	0.003
<b>B</b>	12:49022301-49022301	G/A	missense	KMT2D	-
<b>C</b>	3:25634002-25634002	G/A	missense	TOP2B	$4 \times 10^{-6}$
<b>D</b>	15:72353105-72353105	C/T	missense	HEXA	$5 \times 10^{-5}$
<b>E</b>	4:38797314-38797314	C/A	synonymous	TLR1	0.38
<b>F</b>	7:117639961-117639961	C/T	intron	CFTR	$6 \times 10^{-5}$
<b>G</b>	17:31230383-31230383	G/A	splice_donor	NF1	$4 \times 10^{-6}$
<b>H</b>	11:63290453-63290453	G/A	stop_gained	SLC22A10	0.434



Marth *et al.* (2011) *Genome Biol.* **12**, R84

### 3. EFFECT OF GENETIC VARIANTS

## Functional annotation

Genetic variant	Position	Change	Consequence	Gene	Freq	SIFT	Polyphen	Mutation Assessor	CADD	Condel	LoF tol	RVIS
<b>A</b>	3:1403401-1403401	A/C	missense	CNTN6	0.003	0.47	0	Neutral	9.52	Neutral	0.974	-0.92 (9.81%)
<b>B</b>	12:49022301-49022301	G/A	missense	KMT2D	-	0	1	Medium	32	0.945	-	-5.29 (0.06%)
<b>C</b>	3:25634002-25634002	G/A	missense	TOP2B	$4 \times 10^{-6}$	0.01	0.152	Medium	29.3	0.778	0.82	-0.15 (42.28%)
<b>D</b>	15:72353105-72353105	C/T	missense	HEXA	$5 \times 10^{-5}$	0	1	Damaging	32	0.945	0.17	-0.33 (30.7%)
<b>E</b>	4:38797314-38797314	C/A	synonymous	TLR1	0.38	-	-	-	0.29	-	0.963	1.32 (94.07%)
<b>F</b>	7:117639961-117639961	C/T	intron	CFTR	$6 \times 10^{-5}$	-	-	-	1.08	-	0.0235	-0.51 (21.73%)
<b>G</b>	17:31230383-31230383	G/A	splice_donor	NF1	$4 \times 10^{-6}$	-	-	-	34	-	0.116	-3.09 (0.47%)
<b>H</b>	11:63290453-63290453	G/A	stop_gained	SLC22A10	0.434	-	-	-	36	-	0.7	1.85 (97.12%)

### 3. EFFECT OF GENETIC VARIANTS

## Functional annotation

**G** is the more pathogenic variant.....but is it really pathogenic?





### 3. EFFECT OF GENETIC VARIANTS

- Pathogenic
- Likely pathogenic
- Benign
- Likely benign
- Uncertain significance

**Table 5** Rules for combining criteria to classify sequence variants

Pathogenic	<ul style="list-style-type: none"> <li>(i) 1 Very strong (PVS1) <i>AND</i> <ul style="list-style-type: none"> <li>(a) <math>\geq 1</math> Strong (PS1–PS4) <i>OR</i></li> <li>(b) <math>\geq 2</math> Moderate (PM1–PM6) <i>OR</i></li> <li>(c) 1 Moderate (PM1–PM6) and 1 supporting (PP1–PP5) <i>OR</i></li> <li>(d) <math>\geq 2</math> Supporting (PP1–PP5)</li> </ul> </li> <li>(ii) <math>\geq 2</math> Strong (PS1–PS4) <i>OR</i></li> <li>(iii) 1 Strong (PS1–PS4) <i>AND</i> <ul style="list-style-type: none"> <li>(a) <math>\geq 3</math> Moderate (PM1–PM6) <i>OR</i></li> <li>(b) 2 Moderate (PM1–PM6) <i>AND</i> <math>\geq 2</math> Supporting (PP1–PP5) <i>OR</i></li> <li>(c) 1 Moderate (PM1–PM6) <i>AND</i> <math>\geq 4</math> supporting (PP1–PP5)</li> </ul> </li> </ul>
Likely pathogenic	<ul style="list-style-type: none"> <li>(i) 1 Very strong (PVS1) <i>AND</i> 1 moderate (PM1–PM6) <i>OR</i></li> <li>(ii) 1 Strong (PS1–PS4) <i>AND</i> 1–2 moderate (PM1–PM6) <i>OR</i></li> <li>(iii) 1 Strong (PS1–PS4) <i>AND</i> <math>\geq 2</math> supporting (PP1–PP5) <i>OR</i></li> <li>(iv) <math>\geq 3</math> Moderate (PM1–PM6) <i>OR</i></li> <li>(v) 2 Moderate (PM1–PM6) <i>AND</i> <math>\geq 2</math> supporting (PP1–PP5) <i>OR</i></li> <li>(vi) 1 Moderate (PM1–PM6) <i>AND</i> <math>\geq 4</math> supporting (PP1–PP5)</li> </ul>
Benign	<ul style="list-style-type: none"> <li>(i) 1 Stand-alone (BA1) <i>OR</i></li> <li>(ii) <math>\geq 2</math> Strong (BS1–BS4)</li> </ul>
Likely benign	<ul style="list-style-type: none"> <li>(i) 1 Strong (BS1–BS4) and 1 supporting (BP1–BP7) <i>OR</i></li> <li>(ii) <math>\geq 2</math> Supporting (BP1–BP7)</li> </ul>
Uncertain significance	<ul style="list-style-type: none"> <li>(i) Other criteria shown above are not met <i>OR</i></li> <li>(ii) the criteria for benign and pathogenic are contradictory</li> </ul>

# Functional interpretation


Interpretation of sequence variants | RICHARDS et al

## ACMG STANDARDS AND GUIDELINES

	Benign		Pathogenic			
	Strong	Supporting	Supporting	Moderate	Strong	Very strong
Population data	MAF is too high for disorder BA1/BS1 <i>OR</i> observation in controls inconsistent with disease penetrance BS2			Absent in population databases PM2	Prevalence in affecteds statistically increased over controls PS4	
Computational and predictive data		Multiple lines of computational evidence suggest no impact on gene /gene product BP4  Missense in gene where only truncating cause disease BP1  Silent variant with non predicted splice impact BP7  In-frame indels in repeat w/out known function BP3	Multiple lines of computational evidence support a deleterious effect on the gene /gene product PP3	Novel missense change at an amino acid residue where a different pathogenic missense change has been seen before PM5  Protein length changing variant PM4	Same amino acid change as an established pathogenic variant PS1	Predicted null variant in a gene where LOF is a known mechanism of disease PVS1
Functional data	Well-established functional studies show no deleterious effect BS3		Missense in gene with low rate of benign missense variants and path. missenses common PP2	Mutational hot spot or well-studied functional domain without benign variation PM1	Well-established functional studies show a deleterious effect PS3	
Segregation data	Nonsegregation with disease BS4		Cosegregation with disease in multiple affected family members PP1	Increased segregation data →		
De novo data				De novo (without paternity & maternity confirmed) PM6	De novo (paternity and maternity confirmed) PS2	
Allelic data		Observed in <i>trans</i> with a dominant variant BP2  Observed in <i>cis</i> with a pathogenic variant BP2		For recessive disorders, detected in <i>trans</i> with a pathogenic variant PM3		
Other database		Reputable source w/out shared data – benign BP6	Reputable source – pathogenic PP5			
Other data		Found in case with an alternate cause BP5	Patient's phenotype or FH highly specific for gene PP4			

**Figure 1 Evidence framework.** This chart organizes each of the criteria by the type of evidence as well as the strength of the criteria for a benign (left side) or pathogenic (right side) assertion. Evidence code descriptions can be found in [Tables 3](#) and [4](#). BS, benign strong; BP, benign supporting; FH, family history; LOF, loss of function; MAF, minor allele frequency; path., pathogenic; PM, pathogenic moderate; PP, pathogenic supporting; PS, pathogenic strong; PVS, pathogenic very strong.

## 4. BIOLOGICAL MEANING OF GENETIC VARIANTS




### GENETIC DISEASE

- Mendelian
- Complex

### ADAPTATION

### NEUTRAL

# GENOME WIDE ASSOCIATION STUDIES





**HOW MANY GENETIC VARIANTS IN A GENOME?**



**WHICH TYPE?**



**WHAT EFFECT?**

- SIZE (SNV, indels, CNVS)
- Localization (intergenic, UTRs, exons)
- Frequency (rare, common)
- Nature (somatic, germinal)




**FUNCTIONAL ANNOTATION**

- Primary
- Bioinformatic predictions
- Databases (ClinVar)



**FUNCTIONAL INFORMATION**

- Analyses
- Familiar segregation
- Phenotype/Genotype



**BIOLOGICAL MEANING**

**NEUTRAL**

**ADAPTATION**


**GENETIC DISEASE**

- Mendelian
- Complex

**GENE PROPERTIES**

- Indexes (LoF, RVIS, HI)
- Databases (OMIM)

The expression for all protein-coding genes in all major tissues and organs in the human body can be explored in this interactive database, including numerous catalogues of proteins expressed in a tissue-restricted manner.



# Differential Expression Analysis

1. Mapping & transcript reconstruction
2. Abundance estimation
3. Differential expression (gene level)
4. Enrichment analysis

